 WATERTOWN, Mass., March 03, 2022 GLOBE NEWSWIRE -- Selecta Biosciences, Inc. NASDAQ: SELB, a biotechnology company leveraging its clinically validated, precision immune tolerance platform, ImmTOR, to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, March 10, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021 and provide a business update. 